Impax Laboratories Schedules Conference Call and Webcast for Second Quarter 2010 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)-- Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that its second quarter 2010 financial results will be released before the market opens on Tuesday, August 3, 2010 and will be available on Impax’s Web site at www.impaxlabs.com. The Company will host a conference call and live webcast with financial analysts at 11:00 a.m., Eastern Time.

The live webcast will be accessible through the Investor Relations section of the company's Web site, www.impaxlabs.com.

To access the call through a conference line, dial (877) 356-3814 (in the U.S.) and (706) 758-0033 (international callers) beginning at least 10 minutes prior to the scheduled start of the call.

A replay of the conference call will be available for seven days shortly after the call. To access the replay, dial (800) 642-1687 (in the U.S.) and (706) 645-9291 (international callers). The access conference code is 87118465.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward, Philadelphia and Taiwan facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.



CONTACT:

Impax Laboratories, Inc.
Company Contact:
Mark Donohue
Sr. Director, Investor Relations and Corporate Communications
(215) 933-3526
www.impaxlabs.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Professional Services  Finance  General Health

MEDIA:

Logo
 Logo

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.